The Lancet: November 16, 2007

Arne Astrup from the University of Copenhagen, Denmark, discusses a meta-analysis highlighting how the anti-obesity drug rimonabant is associated with an increased risk of depressive disorders. The meta-analysis pooled data from four randomised trials from the RIO (rimonabant in obesity) programme.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/th...